The energy tail risk no oneโs talking about, why a retail giant got double-downgraded, a candidate for the next IPO pop, and more.
Nov 15, 2025
Apr 18, 2026
โข
1 min read
Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...
Apr 11, 2026
2 min read
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Apr 4, 2026
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.